Fundacion Para La Investigacion Medica Aplicada (FIMA),a not-for-profit foundation part of the Center for Applied Medical Research (CIMA) of the University of Navarra based in Pamplona, Spain, and Vivet Therapeutics have formed a close collaboration involving the exclusive license to Vivet Therapeutics of CIMA's novel proprietary AAV vector gene therapy technology to treat some liver diseases. Vivet Therapeutics and CIMA also work together on several projects to further develop this technology and perform cutting-edge research in several key liver disease areas, such as Wilson's disease.
Vivet holds an exclusive license from the Massachusetts Eye and Ear Infirmary (MEE), a Massachusetts non-profit organization located in Boston, Massachusetts, for use of certain MEE patent-protected ANC 80 AAV vectors in the area of Wilson Disease in particular. The agreement also provides for certain options to additional license rights.
Vivet Therapeutics and its Spanish subsidiary, Vivet Therapeutics SL, are developing new innovative technology and have received a grant from the FEDER (Fonds européen de développement régional de l’Union européenne).